stockrow
Friday 6 November 2026
Export PCRX’s income statement to Excel — free account
Pacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.
- Revenue
- −1.59%
- EPS
- +500.0%
- Free cash flow
- −18.5%
- Total debt
- −37.4%
Quarter to September 2026, against a year earlier
36.44
0.04
+0.11%
Follow PCRX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
26.37 | 72.49 | 188.33 | 172.53 |
+8 more quarters Free account |
P/S ratio |
1.34 | 1.34 | 1.24 | 1.59 | |
P/FCF ratio |
5.91 | 5.58 | 6.89 | 8.44 | |
P/Operating CF |
19.94 | 17.42 | 35.61 | 26.40 | |
P/B ratio |
1.40 | 1.49 | 1.40 | 1.66 | |
Price to Tangible BV |
2.38 | 2.73 | 3.26 | 3.78 | |
EV/Sales |
1.71 | 1.76 | 1.74 | 2.05 | |
EV/EBITDA |
12.32 | 12.77 | 11.21 | 13.76 | |
EV/Operating CF |
7.17 | 7.01 | 9.02 | 9.80 | |
EV/FCF |
7.51 | 7.33 | 9.66 | 10.90 | |
Quick Ratio |
3.32 | 3.14 | 3.01 | 3.01 | |
Current Ratio |
4.68 | 5.04 | 4.73 | 4.54 | |
Net Debt/EBITDA |
0.00 | 4.10 | 5.86 | 6.92 | |
Debt/Assets |
0.00% | 29.19% | 30.42% | 29.42% | |
Debt/Equity |
0.00 | 0.54 | 0.56 | 0.54 | |
Asset Turnover |
0.59 | 0.54 | 0.53 | 0.52 | |
Operating CF/Net income |
1.76 | 12.35 | 8.81 | 26.69 | |
Capex/Depreciation |
0.00 | (0.06) | (0.13) | (0.01) | |
Interest Coverage |
7.72 | 1.18 | 1.87 | 0.60 | |
Research and Development Expense of Revenue |
15.10% | 15.72% | 15.83% | 19.20% | |
Selling, General and Administrative Expense of Revenue |
47.46% | 47.72% | 52.96% | 51.61% | |
Intangible Assets out of Total Assets |
0.24 | 0.25 | 0.31 | 0.31 | |
Share Based Compensation of Revenue |
6.69% | 7.77% | 7.63% | 6.86% | |
Graham Net Nets |
0.10 | 0.04 | (0.04) | (0.02) | |
Graham Number |
19.54 | 11.58 | 6.61 | 7.25 | |
Earnings Yield |
3.79% | 1.38% | 0.53% | 0.58% | |
Free Cash Flow Yield |
16.92% | 17.93% | 14.51% | 11.85% | |
Revenue per Share |
4.43 | 4.88 | 4.38 | 4.42 | |
Operating CF per Share |
1.26 | 1.46 | 0.63 | 0.98 | |
Capex per Share |
(0.09) | (0.03) | (0.07) | 0.00 | |
Free Cash Flow per Share |
1.17 | 1.42 | 0.57 | 0.98 | |
Cash per Share |
7.41 | 6.36 | 5.00 | 5.35 | |
Shareholders Equity per Share |
17.87 | 17.03 | 16.16 | 15.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.87 | 17.03 | 16.16 | 15.55 | |
Free Cash Flow |
46.45 | 56.12 | 22.96 | 43.47 | |
Working Capital |
464.13 | 493.20 | 406.17 | 427.38 | |
Capital Expenditures |
(3.62) | (1.34) | (2.72) | (0.22) | |
Net Current Asset Value |
99.91 | 43.21 | (39.68) | (23.83) | |
EV/EBIT |
35.45 | 66.21 | 53.20 | 77.62 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.00 | |
Price to Operating Income |
27.91 | 50.38 | 37.94 | 60.10 | |
| Other line items | |||||
Average Receivables |
119.08 | 123.39 | 115.19 | 118.69 | |
Average Payables |
17.60 | 23.82 | 18.59 | 17.14 | |
Average Inventory |
143.59 | 141.37 | 142.06 | 139.07 | |
Average Assets |
1,250.11 | 1,390.62 | 1,397.60 | 1,409.22 | |
Average Common Equity |
719.77 | 714.87 | 726.22 | 735.73 |
Columns are period end dates · fundamentals updated 5 Nov 2026